21,162 Shares in Roivant Sciences Ltd. $ROIV Purchased by Legacy Capital Group California Inc.

Legacy Capital Group California Inc. bought a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the fourth quarter, Holdings Channel reports. The firm bought 21,162 shares of the company’s stock, valued at approximately $459,000.

A number of other hedge funds also recently made changes to their positions in ROIV. Goldman Sachs Group Inc. raised its position in Roivant Sciences by 15.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Roivant Sciences by 1.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock valued at $24,678,000 after purchasing an additional 34,341 shares during the period. American Century Companies Inc. raised its position in Roivant Sciences by 1.9% during the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock valued at $1,010,000 after purchasing an additional 1,689 shares during the period. Russell Investments Group Ltd. raised its position in Roivant Sciences by 149.9% during the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock valued at $129,000 after purchasing an additional 6,879 shares during the period. Finally, M&T Bank Corp raised its position in Roivant Sciences by 10.2% during the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after purchasing an additional 1,181 shares during the period. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $28.14 on Friday. The business’s 50 day moving average price is $28.22 and its 200-day moving average price is $23.50. Roivant Sciences Ltd. has a fifty-two week low of $10.58 and a fifty-two week high of $30.33. The company has a market cap of $20.14 billion, a price-to-earnings ratio of -24.05 and a beta of 1.20.

Insider Transactions at Roivant Sciences

In other news, CAO Jennifer Humes sold 13,538 shares of the stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total value of $384,073.06. Following the sale, the chief accounting officer directly owned 84,191 shares in the company, valued at approximately $2,388,498.67. This represents a 13.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Matthew Gline sold 289,774 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the completion of the sale, the chief executive officer owned 16,736,116 shares in the company, valued at approximately $488,025,142.56. The trade was a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 5,085,398 shares of company stock valued at $139,215,946. Company insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ROIV shares. HC Wainwright upped their price objective on Roivant Sciences from $33.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Citigroup upped their price objective on Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Weiss Ratings downgraded Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, February 9th. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Finally, Piper Sandler upped their price objective on Roivant Sciences from $22.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 16th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $30.55.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.